Ventripoint Diagnostics Ltd., a leader in artificial intelligence for echocardiography, announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026 in Padua, Italy. The event, hosted by the University of Padova, focuses on advanced cardiovascular imaging and artificial intelligence, aligning with Ventripoint's core technology.
AEPC, founded in 1963, is the world's largest association in congenital cardiology, uniting over 1,000 specialists from 32 European countries and beyond. The meeting's scientific program centers on imaging and AI, areas where Ventripoint is driving clinical progress. The company will exhibit alongside its European distributor, AngioPro, to engage with clinicians from the global congenital cardiology community.
A key focus at the Ventripoint booth will be the VMS+™ system, which supports monitoring cardiac function over time in congenital heart disease (CHD) patients. The importance of longitudinal assessment is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease (co-endorsed by AEPC), which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for ventricular function assessment.
Ventripoint's priority for 2026 is accelerating integration of VMS+™ into routine clinical practice and building better care pathways for CHD patients. The latest release, VMS+™ 4.0, streamlines workflows, reduces assessment time, and makes advanced cardiac analysis accessible at the point of care. At a patient's first echocardiogram, VMS+™ provides volumetric cardiac measurements equivalent to MRI, supporting clinical decision-making across a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint's VMS+™ product family, powered by proprietary KBR technology developed over more than a decade, delivers volumetric cardiac measurements with accuracy equivalent to MRI. The system is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada. The company's participation at AEPC underscores its commitment to advancing care for CHD patients through AI-driven imaging solutions.
